Prevalence and genotype distribution of human papillomavirus infection among women aged 30–65 years in Xi’an, China: a population-based study of 14,655 women

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Singh GK, Azuine RE, Siahpush M. Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH AIDS. 2012;1:17–30. doi:10.21106/ijma.12.
   PubMedGoogle Scholar
• Duan R, Qiao Y, Clifford G, Zhao F. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. Cancer Med. 2020;9:374–84. doi:10.1002/cam4.2697.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. doi:10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99. doi:10.1016/S0140-6736(13)60022-7.
   PubMed Web of Science ®Google Scholar
• Li J, Gao JJ, Li N, Wang YW. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions. Arch Virol. 2021;166:853–62. doi:10.1007/s00705-021-04960-z.
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015;9:526. doi:10.3332/ecancer.2015.526.
   PubMed Web of Science ®Google Scholar
• Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3–12. doi:10.1016/j.mrrev.2016.07.002.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi:10.1016/S1470-2045(10)70230-8.
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27. doi:10.1056/NEJMoa021641.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21. doi:10.1016/S1470-2045(19)30072-5.
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–57. doi:10.1016/S1470-2045(09)70360-2.
   PubMed Web of Science ®Google Scholar
• Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control. Lancet. 2019;393:969–70. doi:10.1016/S0140-6736(18)32849-6.
   PubMed Web of Science ®Google Scholar
• Kang Y, Sun P, Mao X, Dong B, Ruan G, Chen L. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. J Gynecol Oncol. 2019;30:e29. doi:10.3802/jgo.2019.30.e29.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453–59. doi:10.1016/S1473-3099(07)70158-5.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–99. doi:10.1086/657321.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J. Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women. Hum Vaccin Immunother. 2020;16:1645–52. doi:10.1080/21645515.2019.1689743.
   PubMed Web of Science ®Google Scholar
• Wang XC, Sun LQ, Ma L, Li HX, Wang XL, Wang X. Prevalence and genotype distribution of human papillomavirus among women from Henan, China. Asian Pac J Cancer Prev. 2014;15:7333–36. doi:10.7314/apjcp.2014.15.17.7333.
   PubMedGoogle Scholar
• Li Z, Liu F, Cheng S, Shi L, Yan Z, Yang J. Prevalence of HPV infection among 28,457 Chinese women in Yunnan Province, southwest China. Sci Rep. 2016;6:21039. doi:10.1038/srep21039.
   PubMed Web of Science ®Google Scholar
• Jiang L, Tian X, Peng D, Zhang L, Xie F, Bi C. HPV prevalence and genotype distribution among women in Shandong Province, China: analysis of 94,489 HPV genotyping results from Shandong’s largest independent pathology laboratory. PLoS One. 2019;14:e0210311. doi:10.1371/journal.pone.0210311.
   PubMed Web of Science ®Google Scholar
• Zhang C, Cheng W, Liu Q, Guan Q, Zhang Q. Distribution of human papillomavirus infection: a population-based study of cervical samples from Jiangsu Province. Virol J. 2019;16:67. doi:10.1186/s12985-019-1175-z.
   PubMed Web of Science ®Google Scholar
• Mai Q, Yang X, Cheng H, Wu G, Wu Z. Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China. Hum Vaccin Immunother. 2021;17:965–71. doi:10.1080/21645515.2020.1805993.
   PubMed Web of Science ®Google Scholar
• Xiang F, Guan Q, Liu X, Xiao H, Xia Q, Liu X. Distribution characteristics of different human papillomavirus genotypes in women in Wuhan, China. J Clin Lab Anal. 2018;32:e22581. doi:10.1002/jcla.22581.
   PubMed Web of Science ®Google Scholar
• Hao S, Wang C, Liu S, He J, Jiang Y. HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern. PLoS One. 2020;15:e0230640. doi:10.1371/journal.pone.0230640.
   PubMed Web of Science ®Google Scholar
• Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y. HPV genotype prevalence and distribution during 2009-2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19:90. doi:10.1186/s12905-019-0785-3.
   PubMed Web of Science ®Google Scholar
• Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125:1030–37. doi:10.1002/cncr.32003.
   PubMed Web of Science ®Google Scholar
• Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257. doi:10.1186/s12879-015-0998-5.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82. doi:10.1016/S0140-6736(18)32470-X.
   PubMed Web of Science ®Google Scholar
• Cao D, Zhang S, Zhang Q, Wei X, Zhao M, Ma Q. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: a hospital-based investigation. J Med Virol. 2017;89:1281–86. doi:10.1002/jmv.24748.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677–84. doi:10.1002/ijc.22241.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Epidemiological Studies of Cervical C. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–91. doi:10.1002/ijc.22357.
   PubMed Web of Science ®Google Scholar
• Tay SK, Oon LL. Prevalence of cervical human papillomavirus infection in healthy women is related to sexual behaviours and educational level: a cross-sectional study. Int J STD AIDS. 2014;25:1013–21. doi:10.1177/0956462414528315.
   PubMed Web of Science ®Google Scholar
• Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL, Coursaget P. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol. 2002;31:202–09. doi:10.1093/ije/31.1.202.
   PubMed Web of Science ®Google Scholar
• Crow JM. HPV: The global burden. Nature. 2012;488:S2–3. doi:10.1038/488S2a.
   PubMed Web of Science ®Google Scholar
• Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types in genital warts in Xi’an, China: a prospective study. BMJ Open. 2019;9:e023897. doi:10.1136/bmjopen-2018-023897.
   PubMed Web of Science ®Google Scholar
• Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240–54. doi:10.1038/nrc.2018.13.
   PubMed Web of Science ®Google Scholar
• Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb Mortal Wkly Rep. 2014;63:620–24. PMCID: PMC5779422.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15:172–83. doi:10.1016/S1470-2045(13)70570-9.
   PubMed Web of Science ®Google Scholar